Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $1,050.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective boosted by JPMorgan Chase & Co. from $950.00 to $1,050.00 in a research report report published on Friday,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

Several other brokerages have also recently issued reports on REGN. Truist Financial raised their target price on Regeneron Pharmaceuticals from $772.00 to $780.00 and gave the stock a “buy” rating in a research report on Wednesday, October 7th. TD Cowen upped their price target on shares of Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the company a “buy” rating in a research report on Wednesday, October 21st. Guggenheim upped their price target on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Argus raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 price objective on the stock in a report on Thursday, October 1st. Finally, Sanford C. Bernstein raised their price objective on shares of Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the stock a “market perform” rating in a report on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $872.00.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $927.89 on Friday. The company has a market cap of $95.54 billion, a P/E ratio of 20.49, a price-to-earnings-growth ratio of 1.57 and a beta of 0.10. Regeneron Pharmaceuticals has a 1 year low of $591.52 and a 1 year high of $935.35. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.06 and a quick ratio of 3.66. The stock’s fifty day moving average price is $793.30 and its 200-day moving average price is $738.05.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, topping the consensus estimate of $16.51 by $3.56. The company had revenue of $5.12 billion during the quarter, compared to analyst estimates of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. Regeneron Pharmaceuticals’s revenue was up 36.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $11.83 earnings per share. On average, equities analysts forecast that Regeneron Pharmaceuticals will post 49.10 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be given a dividend of $0.94 per share. The ex-dividend date is Friday, November 20th. This represents a $3.76 annualized dividend and a yield of 0.4%. Regeneron Pharmaceuticals’s payout ratio is 9.29%.

Insider Buying and Selling

In other news, insider Andrew J. Murphy sold 4,147 shares of the firm’s stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the transaction, the insider owned 47,833 shares of the company’s stock, valued at $36,960,559.10. This trade represents a 7.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the transaction, the director directly owned 603 shares in the company, valued at approximately $512,550. The trade was a 39.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 8,093 shares of company stock worth $6,506,845. Company insiders own 6.97% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Boston Trust Walden Corp raised its position in shares of Regeneron Pharmaceuticals by 794.1% during the 3rd quarter. Boston Trust Walden Corp now owns 10,667 shares of the biopharmaceutical company’s stock valued at $8,088,000 after purchasing an additional 9,474 shares during the period. Chicago Partners Investment Group LLC boosted its holdings in Regeneron Pharmaceuticals by 29.7% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 2,865 shares of the biopharmaceutical company’s stock worth $2,306,000 after buying an additional 656 shares during the period. Covestor Ltd boosted its holdings in Regeneron Pharmaceuticals by 31.5% in the 3rd quarter. Covestor Ltd now owns 171 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 41 shares during the period. Compass Financial Management LLC increased its stake in Regeneron Pharmaceuticals by 4,526.2% in the 3rd quarter. Compass Financial Management LLC now owns 3,007 shares of the biopharmaceutical company’s stock worth $2,280,000 after buying an additional 2,942 shares in the last quarter. Finally, Pzena Investment Management LLC purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth $310,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Strong quarterly results: Regeneron reported $5.12 billion in revenue, up 36% year over year and above the $4.58 billion analyst consensus. Adjusted earnings of $20.07 per share also exceeded expectations of $16.51. Regeneron revenue jumps 36% on a bigger Sanofi profit share
• Positive Sentiment: Dupixent remains the primary growth engine: Global quarterly Dupixent sales rose 35% to approximately $6.5 billion, reinforcing the strength of Regeneron’s collaboration with Sanofi and supporting expectations for continued earnings growth. Regeneron: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Pipeline and commercial catalysts: Investors highlighted encouraging Libtayo data in high-risk skin cancer, an expanded BARDA supply agreement for Ebola treatment, and management’s comments about a deep development pipeline. Ongoing share repurchases may also support per-share results. Regeneron Earnings Call Highlights Explosive Growth, Deep Pipeline
• Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, or $3.76 annualized, payable December 3 to shareholders of record November 20. The approximately 0.4% yield is modest but signals continued shareholder returns.
• Neutral Sentiment: Citigroup has forecast further appreciation, while the stock’s breakout to a two-year and 52-week high reflects strong investor momentum. However, the recent rally raises questions about how much future growth is already reflected in the valuation. Regeneron Bolts Higher on Dupixent Dominance
• Negative Sentiment: At roughly $928 per share, Regeneron has risen substantially and may face profit-taking or valuation pressure if future results do not maintain the current pace of growth. Regeneron Stock Looks At A Discount To Earnings

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.